analyst
AR
NASDAQ · ARWR
Arrowhead Pharmaceuticals, Inc.
Healthcare · Biotechnology
$70.67
Down-$10.00 (-12.40%)
Updated Sep 16, 2026, 9:52 AM
SID Score
5.1/10
Composite research score
Smart Money
58/100
Neutral
- Market cap
- 8.86B
- P/E ratio
- 43.81
- Dividend yield
- 0.00%
- 52-week range
- $29.81 – $95.49
- Volume
- 4.37M
- Avg. volume
- 3.18M
Price performance
ARWR price history
1M range · 20 trading sessions · Daily adjusted prices
ARWR closed at $70.67 after 20 trading sessions, down 19.60% for the selected period.
- Last close
- $70.67
- Period change
- -19.60%
- Period low
- $70.67
- Period high
- $89.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $82.89 | $83.55 | $70.605 | $70.67 | 4.37M |
| Sep 14, 2026 | $82.98 | $83.27 | $79.93 | $80.67 | 1.33M |
| Sep 11, 2026 | $83.75 | $85.98 | $82.355 | $82.85 | 1.34M |
| Sep 10, 2026 | $81.58 | $83.38 | $80.33 | $82.76 | 1.02M |
| Sep 9, 2026 | $84.65 | $87.20 | $82.16 | $82.63 | 3.67M |
| Sep 8, 2026 | $84.22 | $86.96 | $83.54 | $85.11 | 1.57M |
| Sep 4, 2026 | $85.87 | $86.96 | $84.2042 | $86.34 | 757.85K |
| Sep 3, 2026 | $85.18 | $86.79 | $83.46 | $86.49 | 1.37M |
| Sep 2, 2026 | $82.87 | $85.47 | $82.085 | $85.37 | 1.53M |
| Sep 1, 2026 | $81.14 | $83.27 | $80.76 | $82.74 | 1.33M |
| Aug 31, 2026 | $83.13 | $83.7554 | $80.75 | $82.39 | 1.6M |
| Aug 28, 2026 | $87.99 | $88.245 | $84.195 | $84.91 | 1.28M |
| Aug 27, 2026 | $89.59 | $89.59 | $88.06 | $88.59 | 857.52K |
| Aug 26, 2026 | $88.45 | $89.825 | $86.80 | $89.12 | 859.49K |
| Aug 25, 2026 | $88.00 | $90.211 | $87.00 | $88.88 | 983.04K |
| Aug 24, 2026 | $86.77 | $87.01 | $85.50 | $86.73 | 1.1M |
| Aug 21, 2026 | $87.90 | $88.46 | $85.94 | $87.11 | 1.09M |
| Aug 20, 2026 | $88.23 | $88.45 | $85.90 | $87.47 | 896.88K |
| Aug 19, 2026 | $89.51 | $90.00 | $87.58 | $89.41 | 1.36M |
| Aug 18, 2026 | $87.72 | $88.35 | $85.98 | $87.90 | 974.99K |
Latest ARWR news
The latest Smart Investors Daily articles mentioning ARWR.
Stock researchCompany · Overview
ARWR research
Overview
Company profile and research snapshot.
Company profile
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $71.00
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 8, 2026 | Citigroup | Buy | — |
| Sep 1, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 31, 2026 | RBC Capital | Outperform | — |
| Aug 31, 2026 | Chardan Capital | Buy | — |
| Aug 6, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
Data unavailable
Market data is busy. Please try again shortly.
AI research layers
Interpretive context generated from the platform’s current data sources.
Data unavailable
Market data is busy. Please try again shortly.